Massive downside potential for biotech SPBIO; upside for inverse, LABD.
Unless there’s some kind of unexpected reversal, LABD is showing its colors … huge upside potential.
As expected, LABD has completed its testing action previously discussed in these two updates; here and here.
At the minimum, we’ve got a right side LABD trend that if followed, will result in a doubling of current price near the end of this month or early next.
A trailing stop can be used which adheres to the (now confirmed) trend; not advice, not a recommendation.
If LABD really is in the channel shown, the top of the range even at this point, is around the 170-level; nearly 550%, from current price.
As always, anything can happen. For now, we’re sitting tight and letting price action dictate the next trading move.
The Project Stimulus account will need to get above the $2,000 level before margin is allowed (by the broker).
By that time, it may be a moot point; volatility could be too high for any kind of size increase.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
While the markets grab headlines of all time highs, biotech’s at the crossroads of collapse.
This site has zeroed in on the most likely candidate to head decisively lower once the bubble has burst.
In fact, if we look at the table of tracked markets below, biotech’s SPBIO, has taken over downside leadership.
Next to last is GDX; the senior mining index.
Repeated many times before, this sector is overcrowded with delusion on both sides. From a trading standpoint, no thank you.
Daily and monthly charts of biotech SPBIO are below. Both charts are inverted and have Fibonacci projections.
The charts are essentially clean so they don’t clutter the data.
Daily SPBIO (inverted):
Monthly SPBIO (inverted):
If SPBIO gets to the extreme Fibonacci projection of 261.8%, it will represent a sector decline of just over -92%.
Sounds about right; not advice, not a recommendation.
Recall, from the 1929 highs to the lows in 1932, was around -84% (depending on the source).
Under those extreme circumstances, -92% decline is not unreasonable.
Of course, if a collapse does happen, it’s not likely to go straight down. The entire ’29 crash did not go straight down either. There were many false rallies on the trip to the bottom.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
After watching and listening to all segments, if you changed the dates, you’d think it’s talking about the here and now.
Three key takeaways are:
Intentional destruction of the food supply
Real unemployment numbers falsified
People starved to death
We can look at today’s payroll data as a pivot point. For whatever reason (out of work, being paid not to work), the economy’s not coming back.
The belief the economy’s going to be stronger once the benefits run out (as stated in the linked article) is false.
The current economy is being intentionally destroyed.
That’s not too hard to determine.
Here’s just one more bit of data (unverified, but still of note) to support that assessment.
If you’re unemployed, starving to death, you’ll be a ready face-diaper wearing compliant subject; easily coerced into being injected (executed).
Obviously, the goal is to be as independent, self-employed as possible so we’re not that person.
Which brings us to the culprit du jour: Biotech.
Yesterday, the expectation was for a reversal and test (that day) before SPBIO continued its downward trajectory (LABD higher).
It looks like the test is lasting two days (maybe more) instead of one.
Inverse fund, LABD is currently trading near 24.15. That’s right in the vicinity of the expected range between 23.90 – 24.30, stated yesterday.
LABD did push a little bit lower in the early session to 23.68, but still within expected range.
LABD is testing the right side channel line and trying its best to break through. Thus far, the low for the day remains at 23.68.
If there’s an upward (LABD) reversal from here, a Fibonacci Day 8, from the original Day 55 low, it would give more confirmation we’re at least following the trendline; potentially at the very right side of a huge trading range.
Stay Tuned
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
It’s possible, after ‘Day 55’, LABD (above) attempted to negate the uptrend (pushing out of the right side) … only to find itself a few days later back in the channel.
Looking at the big picture, could or will LABD reach the upper channel line?
Is that possible?
After the experience with oil futures going negative (last year) the first time in market history, it should be obvious, anything can happen.
If LABD’s in the trading channel shown, we’re still in the early stages of the move.
Today, the expectation is for price action to reverse; coming back to close (or test) near the trend line around 23.90 – 24.30.
If it does and then gaps higher tomorrow (Friday), thus confirming the trend, it’s potentially the last stop for low risk positioning (not advice, not a recommendation).
Otherwise, with LABD up 7%, as of this post, we could already be off to the races.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: The last two links do not verify the veracity of the referenced material. Be advised.
Momentum is building for some kind of ‘tipping point’.
We may be there now.
We’re looking for an avalanche of reports whose combined (fundamental and technical) effect is catastrophic implosion of the biotech sector.
Market Analysis:
The chart speaks for itself. It’s obvious biotech has reversed and could be in serious trouble.
The inverse fund LABD is up a stiff 10.5%, as of this post:
We may or may not have a trading channel as shown.
The right side trendline will need more confirmation. As always, anything can happen and the nascent move could fall apart.
However, what is known:
SPBIO’s (and LABD’s) pivot was called ‘to the day’.
The “Iceberg” notation references this report, where the probability of SPBIO downside at that juncture was presented.
That analysis was correct. SPBIO never looked back.
Positioning:
Our ‘project’ position remains open (not advice, not a recommendation). The correct stance under current circumstances is to let price action take LABD higher.
As Livermore said nearly a century ago, the hard part now is to ‘sit tight’. Let the market determine when the move has ended.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
With price action similar to the Amgen reversal, senior mining index GDX, is testing resistance.
As if taking a cue from yesterday’s report on gold heading lower, today we have gold and the miners deciding to head higher.
All is not what it seems however.
The GDX chart above, shows we’re already in up-thrust condition. There has been a sign of supply (selling overwhelming the buying) and now we’re heading up into a test.
Going back to this report on Amgen, it’s a near exact replica of price action; except it’s (apparently) taking place quicker.
Note the bottom of the ‘Sign of Supply’ is a Fibonacci 8-Days from the high posted on April 21st.
That would naturally lend itself to expect testing action to complete on Fibonacci Day 13, which is this coming Friday.
Remember, that as soon as everyone’s got it figured out (Fibonacci time frame) it changes to something else. So, if no one is really paying attention and still in the hyper-inflation bull camp, they’ll look at this action as a bull move; missing the reversal (when or if it comes).
Tests can fail as well. GDX could push through the resistance and negate the up-thrust.
As stated many times before, the gold market’s too crowded with too many rabid bulls.
This may be a good test and reversal set-up but we’ll stick with shorting biotech (not advice, not a recommendation).
By the way … biotech’s doing very well on the short side today … 🙂
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Even in his trading video, the late David Weis remarks … ‘I have a preference for down markets …’
Profits come nearly twice as fast and the bottom is easier to detect.
With that in mind, the daily chart of inverse biotech fund LABD, has been noted showing both emotions:
Extreme fear shows up as spikes at the trend line. Also noticeable, the spikes are widely spaced.
Greed on the other hand, is spaced closer and harder to detect. Remember, we’re looking at the inverse (LABD); fear and greed locations are swapped.
Moving on to the set-up, the Wyckoff spring:
Considering the current situation … i.e. valuations, margin debt, retail participation extremes, the above forecast is a modest one.
A potential doubling in value (measured move).
The expectation is for LABD to contact the upper trading range somewhere around 27.50 (not advice, not a recommendation).
If it does and then breaks to the upside, a standard measured move (trading range distance, magenta lines) would target the 40-area.
At this juncture, the market (SPBIO) is giving no overt indication of imminent collapse.
This is how markets work.
If we do get the expected wipeout, be prepared for the usual suspects to come out and say ‘No one saw it coming.’
Stay Tuned
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Time and technical have come together; indicating potential downside collapse in biotech.
Collapse potential is immense and has been for years.
Fibonacci 55 days after the 2/10/21, highs, biotech (SPBIO), pivots decisively lower.
Of all the major indices, biotech on a percentage basis, is the downside leader.
Rightly so.
Fundamentally, it’s poised to disintegrate with its illegal, Mengele style campaign of medical experimentation.
Who knows if that full disclosure will happen.
The ‘controllers’, the oligarchs, may come up with some other mechanism to usurp the media, the internet and keep it all under wraps.
However, it looks like the tide’s turning.
Remember, the market leads the news; not the other way around.
If biotech goes into its well deserved collapse, downside action itself will be the catalyst for exposure.
For now, SPBIO is pivoting lower; LABD higher.
The daily chart of LABD shows the Fibonacci time relationship. From low to low; Fibonacci 55 days.
Yesterday, the 28th, was Day 55.
Today, LABD has already posted a new daily high … weighting probability to more upside (SPBIO, lower).
The next chart has the potential trading channel.
It looks aggressive.
However, the market itself has defined the trend.
Shown, in pervious updates, this trend angle has been repeated at least four times from March 5th, LABD high, to yesterday’s low.
It’s no guarantee. We’ll let subsequent price action confirm or negate the right side trend.
As of this post, LABD continues to push aggressively higher.
Our ‘project’ has an open position in LABD.
Without revealing specifics of that position (discussed previously), it’s represented in the table below:
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
It’s mid-session; Amgen (AMGN) is down 7.6%, after a poor earnings report.
The last update on AMGN, linked here, had this to say:
AMGN peaked three days later.
The chart below shows it was a Fibonacci 34-days from the 3/4/21 low, to the 4/21/21, high.
On the fundamental side, we have this explanation for the breakdown.
Missing from the earnings report, not only is customer traffic less this past quarter, it’s going to get (if our research is accurate) a whole lot less as customers literally die-off en masse.
Moving on to biotech SPBIO and 3X inverse, LABD:
As shown in a prior update, LABD has repeating trendline characteristics.
Hourly chart of LABD, below:
We’re still very early at the right side of price action to identify a trend.
However, it’s good to know what LABD ‘likes’ and expect that behavior again.
The daily chart is updated with the Fibonacci 34-day time-frame discussed previously. We’re still within acceptable time error for a potential channel.
If LABD does not reverse significantly higher from here, that potential channel will likely be negated.
Summary:
Linked here, is an article just out on ZeroHedge. It discusses the ‘complacency’ of the market and how it’s ready for a long lasting reversal.
Buried within the report (and claiming ‘fair use’ to quote) we have this nugget:
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Whether or not we’re in the times of the mark (and whether the speck protection is the mark) is of course, debatable.
However, with even a cursory look around, we can see the great deception and the great falling away.
Personally, I presented years ago to family members, that ‘the church’ has become so corrupt, when the time comes, they’ll be the ones distributing the mark.
There’s literally going to be hell to pay for those complicit in this evil.
In a very small way, this site’s doing its part to separate from the complicit; find and walk the narrow path; get the word out.
Back to biotech: Technical and fundamental:
Fundamental:
Obviously, the case against biotech continues to build.
There’s now a site that’s been created to track and document speck related information.
Some of the doctors referenced yesterday (time stamp: 13:32), have started a database cataloguing adverse reactions. Nobody else is doing it. Certainly not big pharma.
LABD (3X inverse SPBIO) downside thrust energy has eroded significantly.
That’s in addition to the largest hourly upward thrust energy spike for LABD since before June 17th, of last year.
Project Stimulus:
Mentioned yesterday, the format of the updates are being changed.
In a cue taken from Dr. Elder about discussing open trades (i.e. not to), at this point, only closed trades will be discussed in the project.
By presenting specific (time, entry, stop, etc.) details on a market action and/or position, that in itself will affect the outcome.
Any engineers reading this will need no further explanation. For more info reference this link.
We’ll leave it with … there’s an open position in LABD. Detail of that position will be discussed when it’s closed.
Thank you,
Stay Tuned
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
The Danger Point® 